ASH: Glofitamab Aids Relapsed, Refractory Diffuse Large B-Cell Lymphoma

MONDAY, Dec. 19, 2022 -- The bispecific antibody that recruits T cells to tumor cells, glofitamab, is effective for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according to a study published online Dec. 11 in the New...